ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$161.89
+1.25%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$165.95
From 52W high−65.79%
Volume1.09M
Market cap$21.68B
P/E (TTM)7.9x
P/S (TTM)4.3x
Div yield—
Key dataNov 4, 2026
Open
$165.95
From 52W high
−65.79%
Volume
1.09M
Market cap
$21.68B
ValuationView details →
P/E (Fwd)
22.2x
EV/EBITDA
15.5x
P/E (TTM)
7.9x
RSI (14)
21.5
MomentumView details →
1D Return
+1.25%
YTD Return
−60.00%
SummaryUpdated Sep 1, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a pioneering biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. The company went public in 2004 and has established itself as a leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating diseases by silencing specific genes that cause illness. Alnylam has successfully commercialized multiple RNAi-based medicines and maintains a robust pipeline targeting both rare genetic diseases and more prevalent conditions including cardiovascular, metabolic, and neurological disorders.
Similar companies
Latest newsMore news →
Alnylam Pharmaceuticals announced that it will present new clinical and real-world data at the AHA Scientific Sessions 2026 and the Intellia Therapeutics, Inc. 2026.1d agoALNYLAM PHARMACEUTICALS, INC. shares fell 25% amid concerns about slower Amvuttra patient starts and demand, despite a third-quarter earnings beat.5d agoALNYLAM PHARMACEUTICALS, INC. reported quarterly earnings of $16.26 per share, above the Zacks Consensus Estimate of $2.19 per share, compared with $2.90 per share a year earlier.6d ago